DMRA
Price
$28.10
Change
+$1.26 (+4.69%)
Updated
Sep 11 closing price
Capitalization
1.74B
48 days until earnings call
Intraday BUY SELL Signals
INBX
Price
$109.27
Change
-$2.15 (-1.93%)
Updated
Sep 11 closing price
Capitalization
1.6B
62 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DMRA vs INBX

DMRA vs INBX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
DMRA vs. INBX commentary
Sep 12, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DMRA is a StrongBuy and INBX is a StrongBuy.

Interact to see
Advertisement
SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
DMRA($1.74B) has a higher market cap than INBX($1.6B). INBX YTD gains are higher at: 38.316 vs. DMRA (22.121). INBX has higher annual earnings (EBITDA): -120.4M vs. DMRA (-270.56M). DMRA has more cash in the bank: 541M vs. INBX (133M). DMRA (0) and INBX (0) have equivalent revenues.
DMRAINBXDMRA / INBX
Capitalization1.74B1.6B108%
EBITDA-270.56M-120.4M225%
Gain YTD22.12138.31658%
P/E RatioN/A0.20-
Revenue00-
Total Cash541M133M407%
Total DebtN/A182M-
FUNDAMENTALS RATINGS
DMRA vs INBX: Fundamental Ratings
DMRA
INBX
OUTLOOK RATING
1..100
8171
VALUATION
overvalued / fair valued / undervalued
1..100
35
Fair valued
93
Overvalued
PROFIT vs RISK RATING
1..100
3237
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
3434
P/E GROWTH RATING
1..100
1007
SEASONALITY SCORE
1..100
27n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

DMRA's Valuation (35) in the null industry is somewhat better than the same rating for INBX (93). This means that DMRA’s stock grew somewhat faster than INBX’s over the last 12 months.

DMRA's Profit vs Risk Rating (32) in the null industry is in the same range as INBX (37). This means that DMRA’s stock grew similarly to INBX’s over the last 12 months.

DMRA's SMR Rating (99) in the null industry is in the same range as INBX (100). This means that DMRA’s stock grew similarly to INBX’s over the last 12 months.

DMRA's Price Growth Rating (34) in the null industry is in the same range as INBX (34). This means that DMRA’s stock grew similarly to INBX’s over the last 12 months.

INBX's P/E Growth Rating (7) in the null industry is significantly better than the same rating for DMRA (100). This means that INBX’s stock grew significantly faster than DMRA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DMRAINBX
RSI
ODDS (%)
N/A
Bearish Trend 2 days ago
76%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bearish Trend 2 days ago
88%
Bearish Trend 2 days ago
89%
MACD
ODDS (%)
Bearish Trend 2 days ago
89%
Bearish Trend 2 days ago
90%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
86%
Bearish Trend 2 days ago
82%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
87%
Bullish Trend 2 days ago
80%
Advances
ODDS (%)
Bullish Trend 2 days ago
87%
Bullish Trend 18 days ago
79%
Declines
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 2 days ago
83%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
90%
Bearish Trend 2 days ago
87%
Aroon
ODDS (%)
Bullish Trend 2 days ago
85%
Bullish Trend 2 days ago
85%
COMPARISON
Comparison
Sep 12, 2026
Stock price -- (DMRA: $28.10 vs. INBX: $109.27)
Brand notoriety: DMRA and INBX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DMRA: 107% vs. INBX: 64%
Market capitalization -- DMRA: $1.74B vs. INBX: $1.6B
DMRA [@Biotechnology] is valued at $1.74B. INBX’s [@Biotechnology] market capitalization is $1.6B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $130.64B. The average market capitalization across the [@Biotechnology] industry is $2.24B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DMRA’s FA Score shows that 1 FA rating(s) are green while INBX’s FA Score has 1 green FA rating(s).

  • DMRA’s FA Score: 1 green, 4 red.
  • INBX’s FA Score: 1 green, 4 red.
According to our system of comparison, both DMRA and INBX are a good buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DMRA’s TA Score shows that 4 TA indicator(s) are bullish while INBX’s TA Score has 4 bullish TA indicator(s).

  • DMRA’s TA Score: 4 bullish, 5 bearish.
  • INBX’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, DMRA is a better buy in the short-term than INBX.

Price Growth

DMRA (@Biotechnology) experienced а -6.52% price change this week, while INBX (@Biotechnology) price change was -9.82% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -6.09%. For the same industry, the average monthly price growth was -3.45%, and the average quarterly price growth was +2531.70%.

Reported Earning Dates

DMRA is expected to report earnings on Oct 30, 2026.

INBX is expected to report earnings on Nov 13, 2026.

Industries' Descriptions

@Biotechnology (-6.09% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
DMRA
Daily Signal:
Gain/Loss:
INBX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SPXE82.090.71
+0.88%
ProShares S&P 500® ex-Energy
DRKY21.500.18
+0.82%
VistaShares Target 15 DRUKMacro Dis ETF
JANU30.490.23
+0.75%
AllianzIM U.S. Equity Buffer15 Uncapped Jan ETF
FYC116.850.68
+0.59%
First Trust Small Cap Gr AlphaDEX® ETF
OBIL49.94-0.01
-0.02%
F/m US Treasury 12 Month Bill ETF

INBX and

Correlation & Price change

A.I.dvisor indicates that over the last year, INBX has been loosely correlated with AXON. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if INBX jumps, then AXON could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To INBX
1D Price
Change %
INBX100%
-1.93%
AXON - INBX
48%
Loosely correlated
+0.10%
SNTI - INBX
39%
Loosely correlated
+1.93%
VCYT - INBX
37%
Loosely correlated
-2.76%
ARRY - INBX
37%
Loosely correlated
+1.54%
SGMT - INBX
35%
Loosely correlated
-1.63%
More